Avenacy debuts generic DDAVP
Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, has launched desmopressin acetate for injection, which is a generic of Ferring Pharmaceutical’s DDAVP for injection.
Desmopressin Acetate for Injection is multi-indicated for patients with central diabetes insipidus, hemophilia A and von Willebrand’s disease (type I).
Avenacy’s desmopressin acetate for injection is available in two presentations: 4 mcg per 1 ml single-dose vials, and 40 mcg per 10 ml multiple-dose vials. In line with Avenacy’s mission to champion patient safety and streamline patient care, desmopressin acetate for injection will feature the company’s highly differentiated packaging and labeling to support accurate medication selection, Avenacy said.
[Read more: Generic sterile injectables market to reach $196.2B by 2029]
Avenacy will begin shipping desmopressin acetate for injection to wholesale partners this week. The company noted that it is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.
Desmopressin acetate for injection had a market value of approximately $39 million for the 12 months ending in June 2023, per IQVIA.